An AI-powered pathology tool called PhenopyCell can accurately predict whether patients with small cell lung cancer will respond to platinum-based chemotherapy, according to a study published March 17 in npj Precision Oncology.
Researchers evaluated the tool on standard pathology slides of 281 patients who were treated for small cell lung cancer at Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center, Atlanta-based Winship Cancer Institute at Emory University and University Hospitals Cleveland Medical Center.
Identifying whether patients will respond to platinum-based chemotherapy will enable patients to “avoid treatments that are unlikely to help them, have a chance to enroll earlier in clinical trials of newer drugs and may get a clearer picture of their prognosis,” Roswell Park said in a March 30 news release.
The research team was led by researchers from Roswell Park and Winship, and included researchers from University Hospitals Cleveland Medical Center, Cleveland-based Case Western Reserve University, Duarte, Calif.-based City of Hope and Hershey, Pa.-based Penn State Cancer Institute.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
